Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. BridgeBio Pharma Inc shares valued at $3,084,313 were sold by Kumar Neil on Jan 09 ’26. At $77.11 per share, Kumar Neil sold 40,000 shares. The insider’s holdings dropped to 715,686 shares worth approximately $55.93 million following the completion of this transaction.
Also, Kumar Neil sold 40,000 shares, netting a total of over 2,958,855 in proceeds. Following the sale of shares at $73.97 each, the insider now holds 735,686 shares.
Before that, KUMAR HALDEA REVOCABLE TRUST U had added 120,000 shares to its account. In a trade valued at $8,912,400, the Director bought BridgeBio Pharma Inc shares for $74.27 each.
As published in their initiating research note from Morgan Stanley on January 06, 2026, BridgeBio Pharma Inc [BBIO] has been an Overweight and the price target has been revised to $96. Analysts at Bernstein started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid December. Earlier on July 21, 2025, Truist initiated its rating. Their recommendation was “a Buy” for BBIO stock.
Analyzing BBIO Stock Performance
On last trading session, BridgeBio Pharma Inc [NASDAQ: BBIO] rose 1.24% to $78.15. The stock’s lowest price that day was $76.83, but it reached a high of $78.56 in the same session. During the last five days, there has been a drop of approximately -1.21%. Over the course of the year, BridgeBio Pharma Inc shares have jumped approximately 131.28%.
Is BridgeBio Pharma Inc subject to short interest?
Stocks of BridgeBio Pharma Inc saw a sharp steep in short interest on 2025-12-31 dropping by -2.17 million shares to 17.21 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 19.38 million shares. A decline of -12.61% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 9.63 of the overall float, the days-to-cover ratio (short ratio) decline to 9.63.
Which companies own the most shares of BridgeBio Pharma Inc (BBIO)?
In terms of BridgeBio Pharma Inc share price expectations, FactSet research, analysts set an average price target of 89 in the next 12 months, up nearly 15.3% from the previous closing price of $77.19. Analysts anticipate BridgeBio Pharma Inc stock to reach 100 by 2026, with the lowest price target being 69. In spite of this, 9 analysts ranked BridgeBio Pharma Inc stock as Buy at the end of 2026. On July 14, 2025, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $70.
